Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Latest shares articles
Forex CFDs: Understanding currency forwards vs spot markets
Spot or forward? These two forex markets behave differently, and now you can trade both with us as forex CFDs. Here’s how they work, and what sets them apart.
14:48, 31 July 2025
Crypto CFDs: Popular cryptocurrencies for trading
Discover which cryptocurrencies are trending for CFD trading in 2025 – from bitcoin to newly listed coins like SUI and PEPE.
10:46, 31 July 2025
Trading the Nasdaq 100 Amidst Big Tech Earnings
Microsoft and Meta notably impressed powering the tech-heavy index higher in the futures market, but it’s two down and two more to go as both Apple and Amazon are next.
07:04, 31 July 2025
Ripple price prediction: Third-party price target
Ripple, launched in 2012 with the XRP Ledger, aims to make cross-border payments faster and cheaper using its native token, XRP. Backed by financial institutions and a strong market presence, it remains a major crypto asset by market cap.
14:34, 30 July 2025
Ratings and Reviews
Ratings and Reviews
